Akari Therapeutics, Plc

05/04/2024

Reminder: Tomorrow at 1pm PT, Akari's Miles Nunn will present at the conference taking place in Seattle, Washington. Learn more: https://bit.ly/49ENCMO

05/01/2024

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics. https://bit.ly/3UBPDF7

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R...

05/01/2024

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity. https://bit.ly/3Qrz0JE

BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the prev...

04/30/2024

Join Chief Scientific Officer, Miles Nunn for Akari's poster presentation at the upcoming conference on Sunday, May 5th, from 1pm to 2:45pm PT. Find details: https://bit.ly/49ENCMO

04/24/2024

Attending the Association for Research in Vision and Ophthalmology 2024 Annual Meeting? Akari CSO Miles Nunn is presenting new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model on May 5th, at 1pm PT. More information can be found here: https://bit.ly/49ENCMO

04/15/2024

Akari will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Officer Miles Nunn will provide an overview of the data in a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT. Find details: https://bit.ly/49ENCMO

04/01/2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights. https://bit.ly/43GiRpi

02/29/2024

Join us today in supporting and the 300 million people worldwide who have rare diseases. Akari is developing advanced therapies for and diseases, including the rare condition . https://bit.ly/3uVvbF6

02/26/2024

This learn about pre-clinical PAS-nomacopan as a potential treatment in (GA) addressing unmet patient needs including longer dose interval and reduction of CNV risk associated with approved GA treatments: https://bit.ly/3Rlji3U

02/20/2024

(GA) patients face risks to sight from both the condition and CNV, a risk associated with approved GA treatments. Learn how PAS-nomacopan with C5+LTB4 inhibition may help address both risks: https://bit.ly/3Rlji3U

02/14/2024

February is ! (GA) is a progressive, sight-threatening condition affecting 5 million people worldwide. Learn about Akari’s pre-clinical research of long-acting PAS-nomacopan as a potential treatment for GA: https://bit.ly/3Rlji3U

01/31/2024

Long-acting PAS-nomacopan is being developed as a treatment with potential for fewer intravitreal injections and reduced risk of sight-threatening choroidal neovascularization (CNV) associated with complement-only inhibitors approved for GA treatment. Learn more:

Akari is conducting a pre-clinical research program to develop long-acting PAS-nomacopan with the potential for three key benefits: complement inhibition, fewer doses, and leukotriene B4 (LTB4) inhibition to address the risks of choroidal neovascularization (CNV) associated complement-only inhibi...